243 related articles for article (PubMed ID: 21590446)
1. Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients.
La-Beck NM; Zamboni BA; Gabizon A; Schmeeda H; Amantea M; Gehrig PA; Zamboni WC
Cancer Chemother Pharmacol; 2012 Jan; 69(1):43-50. PubMed ID: 21590446
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma.
Amantea MA; Forrest A; Northfelt DW; Mamelok R
Clin Pharmacol Ther; 1997 Mar; 61(3):301-11. PubMed ID: 9084455
[TBL] [Abstract][Full Text] [Related]
3. An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin.
Gabizon A; Isacson R; Rosengarten O; Tzemach D; Shmeeda H; Sapir R
Cancer Chemother Pharmacol; 2008 Apr; 61(4):695-702. PubMed ID: 17549475
[TBL] [Abstract][Full Text] [Related]
4. Disseminated classic Kaposi's sarcoma. Two cases with excellent response to pegylated liposomal doxorubicin.
Castiñeiras I; Almagro M; Rodríguez-Lozano J; Fernández-Jorge B; Paradela S; Pozo JD; Fonseca E
J Dermatolog Treat; 2006; 17(6):377-80. PubMed ID: 17853313
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
Hong RL; Tseng YL
Cancer; 2001 May; 91(9):1826-33. PubMed ID: 11335910
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 clinical study of pegylated liposomal doxorubicin (JNS002) in Japanese patients with solid tumors.
Fujisaka Y; Horiike A; Shimizu T; Yamamoto N; Yamada Y; Tamura T
Jpn J Clin Oncol; 2006 Dec; 36(12):768-74. PubMed ID: 17095524
[TBL] [Abstract][Full Text] [Related]
7. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
[TBL] [Abstract][Full Text] [Related]
8. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin.
Martín-Carbonero L; Palacios R; Valencia E; Saballs P; Sirera G; Santos I; Baldobí F; Alegre M; Goyenechea A; Pedreira J; González del Castillo J; Martínez-Lacasa J; Ocampo A; Alsina M; Santos J; Podzamczer D; González-Lahoz J;
Clin Infect Dis; 2008 Aug; 47(3):410-7. PubMed ID: 18582203
[TBL] [Abstract][Full Text] [Related]
9. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
[TBL] [Abstract][Full Text] [Related]
10. Liposomal pegylated doxorubicin versus low-dose recombinant interferon Alfa-2a in the treatment of advanced classic Kaposi's sarcoma; retrospective analysis of three German centers.
Kreuter A; Rasokat H; Klouche M; Esser S; Bader A; Gambichler T; Altmeyer P; Brockmeyer NH
Cancer Invest; 2005; 23(8):653-9. PubMed ID: 16377582
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
[TBL] [Abstract][Full Text] [Related]
12. Monitoring long-term treatment with pegylated liposomal doxorubicin: how important is intensive cardiac follow-up?
Grenader T; Goldberg A; Gabizon A
Anticancer Drugs; 2010 Oct; 21(9):868-71. PubMed ID: 20679886
[TBL] [Abstract][Full Text] [Related]
13. Plasmafiltration as a possible contributor to kinetic targeting of pegylated liposomal doxorubicin (PLD) in order to prevent organ toxicity and immunosuppression.
Martínková J; Bláha M; Kubeček O; Maláková J; Špaček J; Bezouška J; Krulichová IS; Filip S
Cancer Chemother Pharmacol; 2016 Feb; 77(2):429-37. PubMed ID: 26678853
[TBL] [Abstract][Full Text] [Related]
14. Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients.
Ko EM; Lippmann Q; Caron WP; Zamboni W; Gehrig PA
Gynecol Oncol; 2013 Dec; 131(3):683-8. PubMed ID: 24096112
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo characterizations of PEGylated liposomal doxorubicin.
Jiang W; Lionberger R; Yu LX
Bioanalysis; 2011 Feb; 3(3):333-44. PubMed ID: 21320053
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological basis of pegylated liposomal doxorubicin: impact on cancer therapy.
Gabizon A; Shmeeda H; Grenader T
Eur J Pharm Sci; 2012 Mar; 45(4):388-98. PubMed ID: 21933707
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model.
Tuscano JM; Martin SM; Ma Y; Zamboni W; O'Donnell RT
Clin Cancer Res; 2010 May; 16(10):2760-8. PubMed ID: 20460479
[TBL] [Abstract][Full Text] [Related]
18. Age affects pegylated liposomal doxorubicin elimination and tolerability in patients over 70 years old.
Gusella M; Bononi A; Modena Y; Bertolaso L; Franceschetti P; Menon D; Pezzolo E; Barile C; Crepaldi G; Bolzonella C; Inno A; Padrini R; Pasini F
Cancer Chemother Pharmacol; 2014 Mar; 73(3):517-24. PubMed ID: 24442033
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel and pegylated liposomal doxorubicin in recurrent head and neck cancer: clinical and unexpected pharmacokinetic interactions.
Airoldi M; Cattel L; Milla P; Pedani F; Garzaro M; Dosio F
Anticancer Res; 2008; 28(4C):2519-27. PubMed ID: 18751444
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies.
Zamboni WC; Strychor S; Maruca L; Ramalingam S; Zamboni BA; Wu H; Friedland DM; Edwards RP; Stoller RG; Belani CP; Ramanathan RK
Clin Pharmacol Ther; 2009 Nov; 86(5):519-26. PubMed ID: 19675541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
